Press release
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 – − Reported Positive
About this update from Alnylam Pharmaceuticals, Inc.
[{"type":"text","content":"\n− Achieved First Quarter 2023 Global Net Product Revenues of $276 Million, Representing 48% Year-Over-Year Growth Compared to Q1 2022 –\n\n\n− Reported Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, Establishing First-Ever Human Translation of RNAi Therapeutics in CNS –\n\n\n− Reiterated 2023 Financial Guidance, Including Combined Net Product Revenues of $1,200 Million to $1,285 Million –\n\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business highlights.\n\n\n“The first quarter of 2023 saw continued strong commercial execution, driven by the ongoing launch of AMVUTTRA, delivering robust 48% growth in total product sales compared with the first quarter 2022. We also made significant progress with our broad pipeline, delivering positive first-in-human results for an RNAi therapeutic in the CNS from an interim analysis of the Phase 1 study of ALN-APP in patients with early-onset Alzheimer’s disease. We believe this proof of concept is a significant catalyst for future potential growth for Alnylam with the expansion of our product engine to include tissues beyond the liver,” said Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam. “We’re also excited for other key upcoming milestones from our pipeline, including topline Phase 2 results from the KARDIA-1 study of zilebesiran, which are expected mid-year. With this continued execution, we believe we are tracking well toward our Alnylam P5x25 goals of becoming a top-tier biotech company delivering sustained innovation and exceptional financial results.”\n\n\n\n\nFirst Quarter 2023 and Recent Significant Corporate Highlights\n\n\nCommercial Performance\n\n\nTotal TTR: ONPATTRO® (patisiran) & AMVUTTRA® (vutrisiran)\n\n\n\nAchieved global net product revenues for ONPATTRO and AMVUTTRA for the first quarter of $102 million and $102 million, respectively, representing 49% total TTR reported year-over-year growth compared to Q1 2022 and 54% growth on a CER* basis.\n\n\n\nAttained over 3,160 hATTR amyloidosis patients with polyneuropathy worldwide on commercial treatment with ONPATTRO or AMVUT...